{"nctId":"NCT02442284","briefTitle":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection","startDateStruct":{"date":"2015-05-13","type":"ACTUAL"},"conditions":["Chronic Hepatitis C","Cirrhosis","Hepatitis C Virus"],"count":99,"armGroups":[{"label":"3-DAA ± RBV for 12 or 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir","Drug: Ribavirin"]}],"interventions":[{"name":"ombitasvir/paritaprevir/ritonavir and dasabuvir","otherNames":["Viekira Pak","paritaprevir also known as ABT-450","ombitasvir also known as ABT-267","dasabuvir also known as ABT-333"]},{"name":"Ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* US military veteran currently receiving healthcare through the Veterans Health Administration\n* Screening laboratory result indicating hepatitis C virus (HCV), genotype 1-infection\n* Positive for hepatitis C antibodies or HCV RNA at least 6 months before Screening, and HCV RNA \\> 1,000 IU/mL at the time of Screening or HCV RNA \\> 1,000 IU/mL at the time of Screening with a liver biopsy consistent with chronic HCV-infection (or a liver biopsy performed prior to enrollment with evidence of chronic hepatitis C disease)\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding\n* Positive test result for hepatitis B surface antigen (HbsAg) or anti-HIV antibodies (HIV Ab)\n* Prior or current use of any investigational or commercially available anti-HCV agents other than IFN, pegIFN, RBV or sofosbuvir\n* Any current or past clinical evidence of Child-Pugh B or C classification\n* Confirmed presence of hepatocellular carcinoma indicated on imaging techniques within 3 months prior to Screening or on an ultrasound performed at Screening for participants with cirrhosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug. Participants with missing data after backwards imputation were imputed as nonresponders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure During Treatment","description":"On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \\< LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) Among Participants With Ongoing Psychiatric Disorders","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug. Participants with missing data after backwards imputation were imputed as nonresponders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":99},"commonTop":["FATIGUE","HEADACHE","NAUSEA","INSOMNIA","PRURITUS"]}}}